久久国产中文娱乐网_日韓一級高清_a级毛片黄免费观看m_宝贝对着摄像头自己做忘羡_亚洲黄色天堂网_高清有码巨乳日本在线_俄罗斯6一12呦女精品不卡_欧美日批在线观看视频_最近中文字幕更新免費_粉嫩虎白女P虎白女在线

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the humanized amyloid-beta (Aβ) monoclonal antibody “Leqembi?” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great […]

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) reconfirmed today that the regulatory
status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI? (generic name: lecanemab) subcutaneous
(SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows.

Eisai and Biogen announced today that the Ministry of Food and Drug Safety
(MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Aβ)
monoclonal antibody “LEQEMBI?” (lecanemab) for treatment in adult patients with mild cognitive
impairment due to Alzheimer’s disease (AD) or mild AD (early AD).

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa? (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan.